

COPY OF PAPERS
ORIGINALLY FILED

Gp/1653

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Stanley R. Krystek, et al.

Serial No.: 09/853,918

Filed: May 10, 2001

Docket: DB24NP/30436.46USU1

Title: MODIFIED INOSINE 5'-MONOPHOSPHATE DEHYDROGENASE POLYPEPTIDES AND
USES THEREOF

RECEIVED

MAR 28 2002

TECH CENTER 1600/2900

CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this paper or fee is being deposited with the United States Postal as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on March 13, 2002.

By:

Name: Renato Marco P. Domingo

35 N. Arroyo Parkway, Suite 60
Pasadena, California 91103
March 13, 2002Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.8
- ☒ Supplemental Information Disclosure Statement (37 C.F.R. §1.97(b)(3)) (2 pages)
- ☒ Form 1449 (Information Disclosure Statement) (1 sheet)
- ☒ Exhibits 115-116 (2 References)
- ☒ Return postcard

Please charge any additional fees or credit overpayment to Deposit Account No. 50-0306. A duplicate of this sheet is enclosed.

MANDEL & ADRIANO35 No. Arroyo Parkway, Suite 60
Pasadena, California 91103
(626) 395-7801

By:

Sarah B. Adriano

Name: Sarah B. Adriano

Reg. No.: 34,470

Customer No. 26,941



COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

MAR 28 2002

TECH CENTER 1600/290

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Stanley R. Krystek, et al. **Examiner:** Not yet known
Serial No.: 09/853,918 **Group Art Unit:** 1653
Filed: May 10, 2001 **Docket No.:** DB24NP/30436.46USU1
Title: MODIFIED INOSINE 5'-MONOPHOSPHATE DEHYDROGENASE
POLYPEPTIDES AND USES THEREOF

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on March 13, 2002.


By: Renato Marco P. Domingo

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b)(3))

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. They are as follows:

- Burton, Dennis R. and Carlos F. Barbas III, "Human antibodies from combinatorial libraries", *Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man*, Mike Clark (ed.), Academic Titles, Nottingham, pp 65-82, 1993 – **Exhibit 115**
- Griffiths, Andrew D. and Hennie R. Hoogenboom, "Building an *in vitro* immune system: human antibodies from phage display libraries", *Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man*, Mike Clark (ed.), Academic Titles, Nottingham, pp 45-64, 1993 – **Exhibit 116**

This statement should be considered because it is submitted before the mailing date of the first Office Action on the merits according to 37 C.F.R. §1.97(b)(3). In accordance with 37 C.F.R.

Stanley R. Krystek, et al.
Serial No. 09/853,918
Filed: May 10, 2001
Page 2

§1.98(d), copies of Exhibit 1-114 are not provided herein as they have been previously provided before. Copies of Exhibits 115-116 are provided herein.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that the references have been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. § 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-0306.

Respectfully submitted,



Sarah B. Adriano
Registration No. 34,470
Robert D. German
Patent Agent
Registration No. 43,902
Patent Practitioners for Applicants
Mandel & Adriano
35 No. Arroyo Parkway, Suite 60
Pasadena, California 91103
(626) 395-7801
Customer No. 26,941

**INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION**

Docket Number	Application Number
DB24NP/30436.46USU1	09/853,918
Applicant	
Stanley R. Krystek et al.	
Filing Date	Group Art Unit
May 10, 2001	1653

[illegible]

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	✓	Burton, Dennis R. and Carlos F. Barbas III, "Human antibodies from combinatorial libraries", <i>Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man</i> , Mike Clark (ed.), Academic Titles, Nottingham, pp 65-82, 1993 (Exhibit 115)
	✓	Griffiths, Andrew D. and Hennie R. Hoogenboom, "Building an <i>in vitro</i> immune system: human antibodies from phage display libraries", <i>Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man</i> , Mike Clark (ed.), Academic Titles, Nottingham, pp 45-64, 1993 (Exhibit 116)

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE